November 20, 2018

We would like to use this opportunity to inform you that we have now started the human clinical safety trial in UK and the first patients are now enrolled. Read more

June 11, 2018

We are very pleased to announce that we late yesterday received the permission from MHRA (UK health authorities) to start the CE mark human trial, read more

May 16, 2018

March 14, 2018

We are pleased to inform that we have now received another MNOK 10,0 (tranche 2 of 3 tranches) from the investor consortium that joined us last fall. Read the letter

December 20, 2017

Biovotec has successfully completed its preclinical safety studies and is now ready to apply for its clinical studies, see attached for more information. 

October 11, 2017

Biovotec announces today that it has raised MNOK 10,0 in a private placement and has secured further funding of an additional MNOK 20,0 conditioned on reaching predefined milestones….

Press realease

May 15, 2017

Biovotec has as communicated in the General Assembly on the 26th of February 2017 used it´s mandate to raise MNOK 5,0 . The funds will support the ongoing operations and trials, and will give Biovotec the freedom to build momentum going forward. The share price was NOK...

Please reload

Please reload

Recent Posts
Please reload

Media Contact:     +47 95 94 99 78

Engebrets vei 3, 0275 Oslo, Norway                                                   © Biovotec AS                                                                       info@biovotec